Navigation Links
WuXi PharmaTech Congratulates the 2010 Nobel Laureates in Chemistry

SHANGHAI, Oct. 10 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today extended its congratulations to Dr. Richard Heck, Dr. Ei-ichi Negishi, and Dr. Akira Suzuki on winning the 2010 Nobel Prize in Chemistry. The prize was awarded for the development of palladium-catalyzed cross coupling, which has vastly improved the ability of chemists to create sophisticated chemical compounds. Dr. Negishi spoke at WuXi headquarters in July in the company's Science Seminar Series.

Dr. Negishi graduated from the University of Tokyo in 1958 and did his internship at Teijin Ltd., a Japanese pharmaceutical and chemical company. He earned a Ph.D. from the University of Pennsylvania in 1963 under the supervision of Dr. Allan Day. In 1966, he became a postdoctoral researcher at Purdue University, and he served as assistant to Nobel laureate Dr. Herbert Brow beginning in 1968. He was appointed assistant professor of chemistry at Syracuse University in 1972 and full professor at Purdue University in 1979. Dr. Negishi is the author or co-author of more than 375 papers, 30 essays, and two books.

WuXi scientists were highly impressed by Dr. Negishi's lectures in July, titled "Evolution of the Pd-Catalyzed Cross-Coupling for C-C Bond Formation: Complementary with the Grignard Chemistry" and "Zirconium-Catalyzed Asymmetric Carboalumination of Alkenes." The WuXi PharmaTech Science Seminar Series is a monthly program that invites the world's top scientific minds and leaders in the pharmaceutical industry to speak to the company's scientists. The program aims to keep them informed about the latest developments in a broad range of topics in pharmaceutical research and development.

"Congratulations to Dr. Negishi, Dr. Heck, and Dr. Suzuki on winning the 2010 Nobel Prize in Chemistry," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec. "I would again like to extend my sincere appreciation to Dr. Negishi for sharing his expertise and knowledge with WuXi PharmaTech's scientists. We have gained inspiration and insight from these world-class scientists." For more information, please contact:Stephanie Liu (for the media)Tel:   +86-21-5046-4362Email: Stephanie_liu@wuxiapptec.comRonald Aldridge (for investors)Tel:   +1-201-585-2048Email:

SOURCE WuXi PharmaTech
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
2. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
3. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
4. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
5. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
6. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
7. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
8. WuXi PharmaTech Announces Third Quarter 2008 Results
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
11. Pharmatech 2.0: Introducing Pharmatech Oncology
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):